MedTrace Logo

Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy

NCT05223608 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 651

Last updated 2026-03-30

No results posted yet for this study

Summary

ImmuCCo-1905 is a monocentric interventional study on patients treated by immunotherapy, which consist in establishment of a prospective clinic-biologic database over 5 years, associated with a biobank. This database will allow carrying out works aiming at assessing immunotherapy in real life situation.

Conditions

  • Solid Tumor, Adult

Interventions

OTHER

ImmuCCo Cohort

Blood sampling at initiation of immunotherapy, at the first tumor assessment, in case of severe toxicity. Urine collection at initiation of immunotherapy.

Sponsors & Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Centre Oscar Lambret

    lead OTHER

Principal Investigators

  • Alexandra FORESTIER, MD · Centre Oscar Lambret

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-03
Primary Completion
2027-03-31
Completion
2028-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05223608 on ClinicalTrials.gov